Novo Nordisk B

Novo Nordisk shares rise as new oral semaglutide data show equal efficacy to injections, with Medicare GLP‑1 Bridge program and price cuts boosting patient access and adherence.

Novo Nordisk’s new semaglutide data and Medicare bridge program lift its weight‑loss portfolio, boosting sales outlook and strengthening payer access while navigating GLP‑1 competition.

Novo Nordisk expands Irish production to launch Wegovy tablet, tackling Eli Lilly’s competition while maintaining margins and boosting global weight‑loss market leadership.

New Wegovy HD: Novo Nordisk’s low‑price high‑dose semaglutide launches on GoodRx, aiming to boost volume in the self‑pay obesity market while holding margins and countering Lilly’s new oral competitor.

Discover how Novo Nordisk’s new oral GLP‑1 weight‑loss drug balances proven weight‑loss benefits, lower pricing, and competitive pressures in the U.S. market.

Discover how Novo Nordisk’s new EMA approval for simplified Wegovy administration strengthens its dominance in the expanding weight‑loss market, balancing pricing power against rising generic competition.

How Novo Nordisk’s pricing, reimbursement, and competition shifts reshape GLP‑1 profits and global strategy.

Explore how Novo Nordisk’s Wegovy subscription model, workforce cuts, and new semaglutide cardiovascular findings reshape U.S. GLP‑1 pricing, reimbursement, and growth prospects.

How Novo Nordisk is navigating Brazil price caps, U.S. GLP‑1 competition and tariff threats while keeping Ozempic® and Wegovy® accessible.

How Novo Nordisk is using subscription pricing, digital‑health partnerships, NICE approvals, and price cuts to protect its GLP‑1 market leadership amid patent erosion and rising competition.